This Is Not The Medical Marijuana Stock That You Want

I like the risk-reward situation here, at a market cap under $700 million, than I did when the company was over $1.2 billion, but only for an investor that’s willing to hold for multiple years. In this biotech market, it’s hard to say whether GW Pharmaceuticals has hit bottom, especially since it’s trading considerably higher than it was a year ago.

Investors may need to wait until one of the other pipeline drugs is approved before GW Pharmaceuticals reaches its full potential. Look beyond medical marijuana (and don’t let your portfolio go up in smoke) They said it couldn’t be done.

But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger.

To read more visit

Posted in: Investing, News

Comments are closed.

For updates, news and tips
Your valid email will receive a confirmation for this subscription